Administration of CI-1033, an irreversible Pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study

被引:63
作者
Calvo, E
Tolcher, AW
Hammond, LA
Patnaik, A
de Bono, JS
Eiseman, IA
Olson, SC
Lenehan, PF
McCreery, H
LoRusso, P
Rowinsky, EK
机构
[1] Univ Texas, Inst Drug Dev, Canc Therapy & Res Ctr, Hlth Sci Ctr, San Antonio, TX 78229 USA
[2] Ann Arbor Labs, Pfizer Global Res & Dev, Ann Arbor, MI USA
[3] Wayne State Univ, Ctr Hlth, Detroit, MI USA
关键词
D O I
10.1158/1078-0432.CCR-04-1187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmaco fkinetic behavior. Experimental Design: Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other week were administered to patients with advanced solid malignancies. Plasma concentration-time data sets from all evaluable patients were used to develop a population pharmacokinetic model. Noncompartmental methods were used to independently assess the effect of a high-fat meal on CI-1033 absorption and bioavailability. Results: Twenty-four patients were treated with 69 twenty-eight day courses. The incidence of unacceptable toxicity, principally diarrhea and skin rash, was observed at the 300 mg/day dose level. At the 250 mg/day level, toxicity was manageable, and protracted administration was feasible. A one-compartment linear model with first-order absorption and elimination adequately described the pharmacokinetic disposition. CL/F, apparent volume of distribution (V-d/F), and k(a) (mean +/- relative SD) were 280 L/hour +/- 33%, 684 L +/- 20%, and 0.35 hour(-1) +/- 69%, respectively. C-max values were achieved in 2 to 4 hours. Systemic CI-1033 exposure was largely unaffected by administration of a high-fat meal. At 250 mg, concentration values exceeded IC50 values required for prolonged pan-erbB tyrosine kinase inhibition in preclinical assays. Conclusions: The recommended dose on this schedule is 250 mg/day. Its tolerability and the biological relevance of concentrations achieved at the maximal tolerated dose warrant consideration of disease-directed evaluations. This intermittent treatment schedule can be used without regard to meals.
引用
收藏
页码:7112 / 7120
页数:9
相关论文
共 45 条
  • [11] Food and Drug Administration, 2002, GUID IND FOOD EFF BI
  • [12] THE EPIDERMAL GROWTH-FACTOR RECEPTOR AS A PROGNOSTIC MARKER - RESULTS OF 370 PATIENTS AND REVIEW OF 3009 PATIENTS
    FOX, SB
    SMITH, K
    HOLLYER, J
    GREENALL, M
    HASTRICH, D
    HARRIS, AL
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1994, 29 (01) : 41 - 49
  • [13] Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3
  • [14] Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
    Fry, DW
    Bridges, AJ
    Denny, WA
    Doherty, A
    Greis, KD
    Hicks, JL
    Hook, KE
    Keller, PR
    Leopold, WR
    Loo, JA
    McNamara, DJ
    Nelson, JM
    Sherwood, V
    Smaill, JB
    Trumpp-Kallmeyer, S
    Dobrusin, EM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) : 12022 - 12027
  • [15] GARRISON M, 2001, P 37 ANN M AM SOC CL, pA72
  • [16] Giatromanolaki A, 1996, ANTICANCER RES, V16, P3819
  • [17] GONG X, 2001, P 92 ANN M AM ASS CA, P674
  • [18] Targeting the HER-kinase axis in cancer
    Gross, ME
    Shazer, RL
    Agus, DB
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 9 - 20
  • [19] Developing inhibitors of the epidermal growth factor receptor for cancer treatment
    Grünwald, V
    Hidalgo, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12): : 851 - 867
  • [20] HIRONO Y, 1995, ONCOLOGY, V52, P182